U.S. Beverage Stock News

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...

Why the activist letter matters for First Industrial Realty Trust (FR) On February 26, Land & Buildings Investment Management publicly challenged First Industrial Realty Trust (FR), criticizing its boardroom culture and urging changes it says are needed to address the REIT’s trading discount and unlock more value. See our latest analysis for First Industrial Realty Trust. At a share price of US$63.14, First Industrial Realty Trust has logged an 11.03% 1 month share price return and a 14.42% 1...

Olema Pharmaceuticals (OLMA) has been drawing attention after recent share price swings, with the stock at US$24.20 and mixed returns over the past month, past 3 months, and year to date, prompting fresh investor scrutiny. See our latest analysis for Olema Pharmaceuticals. While the recent 1 day and 30 day share price returns show modest declines from US$24.20, the very large 1 year and 3 year total shareholder returns suggest earlier optimism around Olema Pharmaceuticals is now being...

In February 2026, Everus Construction Group, Inc. reported fourth-quarter 2025 sales of US$1,011.47 million and net income of US$55.28 million, alongside full-year 2025 sales of US$3.75 billion and net income of US$201.77 million, and issued 2026 revenue guidance of US$4.1 billion to US$4.2 billion. Management also underscored that Everus is actively pursuing accretive acquisitions, backed by a strong balance sheet, expanded corporate development capabilities and a broader M&A pipeline...

Dole plc has reported fourth-quarter 2025 sales of US$2,366.16 million with a net loss of US$2.66 million, alongside full-year 2025 sales of US$9,172.91 million and net income of US$51.32 million, while affirming a US$0.085 per-share quarterly dividend and completing a 300,000-share buyback. Beyond the headline figures, Dole exited its Fresh Vegetables division, authorized up to US$100 million of share repurchases, and is targeting at least US$400 million of adjusted EBITDA for 2026,...

Analyst reaction to Duke Energy’s nuclear reliability milestone Duke Energy (DUK) has drawn fresh attention after reporting record 2025 nuclear fleet reliability of 96.9%, tied to roughly US$600 million in federal nuclear production tax credits passed through to customers. Recent analyst commentary has linked this operational update to a stronger earnings outlook and increased confidence in the company’s long term execution. This has prompted many investors to take a closer look at the...

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...

Atlanta Braves Holdings (BATR.K) is back in focus after its latest quarterly earnings and the announcement of BravesVision, a new in-house local broadcast platform that is set to reshape how the team monetizes its media rights. See our latest analysis for Atlanta Braves Holdings. The latest earnings beat and BravesVision announcement come after a 10.79% 1 month share price return and a 9.73% year to date share price return, while the 5 year total shareholder return of 46.93% points to...

In February 2026, Lennar disclosed that the Illinois State Treasurer submitted a shareholder proposal seeking vote-by-share-class reporting, while another proposal urged the company to move toward a one-share, one-vote structure, ahead of its April 8, 2026 annual meeting. These governance-focused proposals highlight growing investor pressure for greater transparency and voting equality at Lennar, even as the company continues expanding communities like Cedar Springs in Alabama. We’ll now...

Vericel (VCEL) just paired record fourth quarter results with fresh 2026 guidance. This puts its MACI franchise, expanding sales force, and new manufacturing plans in the spotlight for investors watching the stock. See our latest analysis for Vericel. The earnings and 2026 guidance arrived alongside some pressure on the share price, with a 1-day share price return of a 5.31% decline and a 7-day share price return of a 6.33% decline. The 1-year total shareholder return of a 30.43% decline...

Burlington Stores (NYSE:BURL) plans to open 110 net new stores in 2026, ahead of earlier expectations. The company is also expanding its corporate office footprint in New York to support a larger organization. These moves reflect management's intent to scale operations and reinforce Burlington's long term growth plans. Burlington Stores comes into this announcement with its shares at $306.62 and a 1 year return of 23.0%. Over 3 years the stock has returned 41.8%, and over 5 years 9.8%,...

Carvana (CVNA) is back in focus after its latest results showed quarterly and full year revenue and net income figures that were well above the prior year, alongside an updated long term growth plan. See our latest analysis for Carvana. Despite the strong earnings headlines, the share price has been volatile, with a 30 day share price return of 18.35% and a year to date share price decline of 16.35%. At the same time, the 1 year total shareholder return of 43.63% and very large 3 year total...

Asana has launched its AI-powered work management platform in the AWS Middle East (UAE) Region. The company is among the first enterprise collaborative solutions available on AWS Marketplace for this market. The rollout focuses on regulated and public sector customers that require data residency and enterprise-grade security controls. For investors following NYSE:ASAN, this move comes with the stock trading around $7.06 and showing pressure across multiple timeframes, including a 36.5%...

Salesforce (CRM) is back in focus after a busy quarter that combined a Q4 earnings beat, a new US$50b share repurchase authorization, a higher dividend, and fast growing AI driven Agentforce revenue. See our latest analysis for Salesforce. Even with the AI and buyback headlines, Salesforce’s recent share price performance has been weak. The 30-day share price return was 14.95%, and the year-to-date share price return was a 23.56% decline. The 1-year total shareholder return showed a 34.49%...

Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a more cautious outlook for Syfovre. See our latest analysis for Apellis Pharmaceuticals. The recent earnings release and more cautious commentary around Syfovre seem to have weighed on sentiment, with a 7 day share price return of 6.01% decline and a year to date share price return of 19.03%...

Enviri (NVRI) is back on investors’ radars after recent trading left the shares around $18.93, with returns over the past month, past 3 months, and year showing mixed but meaningful moves. See our latest analysis for Enviri. Recent trading around $18.93 follows a 1 day share price return of 1.83%, while the 90 day share price return of 3.22% sits alongside a very large 1 year total shareholder return of 191.23%. This suggests that momentum has been building over a longer stretch rather than...

Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million and basic EPS of US$6.44. Over the past few quarters, the company has seen revenue move from US$42.8 million in Q4 2024 to US$45.3 million in Q1 2025, US$47.6 million in Q2 2025, US$115.5 million in Q3 2025 and US$59.7 million in Q4 2025, alongside basic EPS ranging from a loss of US$2.21 in Q1...

Unity Software (NYSE:U) is reviewing options for its China business, including a possible sale of its Chinese operations. The review focuses on how the company structures and potentially exits part or all of its presence in one of the largest digital markets. The outcome could influence how Unity allocates resources across regions and product lines in the future. For investors tracking NYSE:U, this review comes after a difficult period for the stock. Shares recently closed at $18.23, with a...

Recent analysis of Nutex Health’s hybrid model of micro-hospitals, hospital management services, and population health programs highlighted strong profitability metrics and claims of deep undervaluation, drawing fresh investor attention in the past week. An interesting angle is the company’s high free cash flow conversion, which some commentators argue could support a meaningful reassessment of its valuation if operating performance holds. We’ll now examine how Nutex Health’s highlighted...

Centrus Energy has in recent months secured a US$900 million High-Assay Low-Enriched Uranium contract from the U.S. Department of Energy and committed hundreds of millions of dollars to expand its Oak Ridge and Piketon enrichment plants, reinforcing its role in a reshaped Western nuclear fuel supply chain. An important takeaway is that Centrus now sits at the center of a multi‑billion‑dollar backlog through 2040, reflecting how policy shifts away from Russian uranium have turned its unique...

AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering. Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal...

International Seaways (INSW) is back in focus after reporting record fourth quarter net income and pairing those results with its largest ever quarterly dividend, a combined US$2.15 per share. See our latest analysis for International Seaways. The latest earnings and dividend news has arrived after a strong run in the shares, with a 30 day share price return of 26.6% and a year to date gain of 60.74%. That move sits on top of a very large 1 year total shareholder return of 143.19% and a 5...

Morgan Stanley and UBS recently upgraded Ermenegildo Zegna Group, following Q4 2025 sales that came in ahead of earlier expectations and highlighted broad-based strength in the core Zegna brand. Analysts pointed to strong engagement from Western affluent consumers across generations as evidence that Zegna’s brand and product positioning are resonating across key demographics. We’ll now examine how this renewed analyst confidence, driven by stronger-than-expected Q4 sales, may influence...